Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company, announced its financial results for the fourth quarter ended December 31, 2025, revealing a revenue of $0.7 million, consistent with the same period in 2024. The company reported a net loss of $29.6 million for the quarter, slightly higher than the $29.0 million loss in Q4 2024. Research and development expenses increased to $25.3 million, driven by advancements in internal programs, particularly the ABS-201 and ABS-101 clinical trials. The company highlighted that it has successfully dosed the first three cohorts in the single ascending dose (SAD) portion of its ongoing Phase 1/2a HEADLINE trial for ABS-201, which targets androgenetic alopecia (AGA). The trial has shown favorable emerging safety data, and interim proof-of-concept data is expected in the second half of 2026. Additionally, Absci is preparing to initiate a Phase 2 clinical trial for ABS-201 in endometriosis by the end of 2026, addressing a significant unmet medical need in this area. The company also appointed Dr. Ransi Somaratne as Chief Medical Officer to lead clinical execution and strategy. Absci's cash, cash equivalents, and marketable securities are projected to be sufficient to fund operations into the first half of 2028, indicating a stable financial position as it advances its clinical programs.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.